Nuformix plc (LON:NFX – Get Free Report) rose 4.3% on Monday . The stock traded as high as GBX 0.09 ($0.00) and last traded at GBX 0.07 ($0.00). Approximately 4,040,659 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 82,439,656 shares. The stock had previously closed at GBX 0.07 ($0.00).
Nuformix Trading Up 6.7 %
The firm has a market cap of £655,448.00, a price-to-earnings ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The business has a 50-day moving average of GBX 0.06 and a 200-day moving average of GBX 0.09.
Nuformix (LON:NFX – Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- What is an Earnings Surprise?
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- What is a Dividend King?
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
